Hexamethylene bisacetamide

white crystalline powder or flakes

N,N′-Hexamethylene bis(acetamide) was used as an inducing agent in obtaining mononuclear cells from the peripheral blood (PB) sample by Ficoll-Hypaque gradient separation.

Hexamethylene bisacetamide is a tumor cell-differentiating agent. It induces complete differentiation of 754A murine erythroleukemia cells when used at a concentration of 5 mM. Hexamethylene bisacetamide also induces latent HIV-1 viral production in chronically HIV-1-infected U1 cells in a concentration-dependent manner. Implantation of HT-29 colon cancer cells cultured with hexamethylene bisacetamide for seven days, but not 28, reduces tumorigenesis of those cells in mice. Hexamethylene Bisacetamide (HMBA) is a hybrid polar compound originally developed as a differentiation-inducing agent. HMBA can inhibit the activation of several NF kappaB target genes in both lung and breast cancer cell lines. Furthermore, consistent with its ability to inhibit NF kappaB function, HMBA can also sensitize cells to apoptosis. HMBA mediates inhibition of the Akt and ERK/MAPK cascade, both critical for cell survival and proliferation and are well-known regulators of NF kappaB activation[1].